[HTML][HTML] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Frontiers in …, 2019 - frontiersin.org
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Frontiers in …, 2019 - europepmc.org
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
[HTML][HTML] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Frontiers in …, 2018 - ncbi.nlm.nih.gov
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177 Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177 Lu)-Dotatate for the treatment of somatostatin …
[PDF][PDF] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Front
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Oncol, 2019 - scienceopen.com
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
PM Kasi, CL Maige, F Shahjehan… - Frontiers in …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177 Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177 Lu)-Dotatate for the treatment of somatostatin …
[PDF][PDF] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Front
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Oncol, 2019 - academia.edu
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
A care process model to deliver177Lu-DOTATATE peptide receptor radionuclide therapy for patients with neuroendocrine tumors
PM Kasi, CL Maige, F Shahjehan… - Frontiers in …, 2019 - mayoclinic.elsevierpure.com
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.
PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Frontiers in …, 2019 - europepmc.org
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …